IL37 and cancer: The genomes of cancers deficient in mismatch repair (MMR) contain exceptionally high numbers of somatic mutations.28 According to a phase II study, dMMR CRCs were sensitive to immune checkpoint blockade with anti‐PD‐1 antibodies.29 Recent evidence supports the hypothesis that the large proportion of mutant neoantigens in dMMR cancers make them sensitive to immune checkpoint blockade, regardless of the cancers’ tissue of origin.27 IL‐37 has shown anti‐inflammatory and immune suppression effects.